NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Kyntra Bio, Inc. KYNB
13 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 6.4M
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2025 · Revenue 6.4 · Net income 183.5
Compound annual growth
Revenue compounded at −48.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
2849 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating -712.7% · Net 2848.6%
ROE
FY2022 · ROE -312.9%
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 |
| Operating income $B | −0.0 | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.3 | −0.3 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| Income tax $B | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.2 | −0.0 | −0.3 | −0.3 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.0 | −0.1 | −0.3 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.0 | 0.0 | 0.0 |
| EPS, diluted $ | 45.37 | −11.89 | −2.92 | −3.14 | −3.14 | −2.11 | −0.89 | −1.03 | −1.66 | −0.93 | −1.42 | −3.17 | −1.13 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | −312.9 | −91.9 | −40.3 | −15.0 | −16.7 | −35.3 | −34.8 | −43.0 | −26.9 | · |
| Shares out B | 0.00 | 0.00 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.06 | 0.06 | 0.06 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 50 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 38 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013